Anaptysbio (ANAB) Stock News

Anaptys (Nasdaq: ANAB) reported late-breaking Phase 2b results for rosnilimab in rheumatoid arthritis on Oct 29, 2025, from a global 424-patient trial presented at ACR Convergence 2025. Primary Week 12 efficacy on DAS28-CRP and ACR20 was confirmed and responses deepened by Week 28, including CDAI low disease activity and CDAI remission, independent of prior advanced therapies including JAK inhibitors.

Responses remained durable for at least three months off drug. Safety through Week 38 showed rosnilimab was well-tolerated with no treatment-related serious adverse events, no malignancies, and no deaths; Tph cells were reduced by >90% by Week 6.

Anaptys (NASDAQ: ANAB) announced that complete Phase 2b data for rosnilimab in rheumatoid arthritis will be presented as a late-breaking oral at ACR Convergence 2025 in Chicago on Oct 29, 2025 from 8:00–9:30am CT.

The company described rosnilimab as a pathogenic T cell depleter that produced a compelling safety and tolerability profile and JAK-like efficacy through six months, with effects that were reported as durable for at least three months off-drug. Paul Emery, M.D., University of Leeds, will present (Abstract ID 2215555). The presentation will be available for download from the company website after the session.

AnaptysBio (NASDAQ:ANAB) announced a virtual investor event scheduled for October 14, 2025, at 4:30 PM ET to discuss ANB033, their CD122 antagonist therapeutic candidate. The presentation will feature Dr. Joseph A. Murray from Mayo Clinic alongside the company's management team.

The event will cover three key areas: ANB033's mechanism of action as a CD122 receptor antagonist, preclinical and initial Phase 1a data from healthy volunteers, and celiac disease biology along with Phase 1b trial design. A Q&A session will follow the presentation, with a live webcast available on the company's investor relations website.

AnaptysBio (NASDAQ:ANAB) announced plans to split into two independent, publicly traded companies by year-end 2026. The first entity, temporarily named Royalty Management Co, will manage royalties from collaborations including GSK's Jemperli (generating $482M in 1H 2025) and Vanda's imsidolimab. The second entity, Biopharma Co, will focus on developing immunology therapeutics, including rosnilimab, ANB033, and ANB101.

Key financials include Jemperli's tiered royalties of 8-25% on net sales, with GSK projecting peak sales of £2 billion ($2.7B). The Vanda collaboration could yield up to $35M in milestones plus 10% royalties. Current Jemperli royalties are directed to Sagard until reaching $600M by 2031 or $675M thereafter, with an estimated $250M accrued through 2025.

AnaptysBio (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, has announced its participation in three major investor conferences in September 2025.

The company's leadership, including CEO Daniel Faga, will participate in fireside chats and one-on-one investor meetings at the Cantor Global Healthcare Conference (Sept. 3), Wells Fargo Healthcare Conference (Sept. 4), and Stifel Virtual Immunology and Inflammation Forum (Sept. 16). All sessions will be available via webcast on the company's investor relations website.

AnaptysBio (NASDAQ:ANAB) reported Q2 2025 financial results and significant clinical progress. The company announced positive Phase 2b data for rosnilimab in rheumatoid arthritis, showing JAK-like efficacy and durable responses. Enrollment was completed for the Phase 2 ulcerative colitis trial, with top-line data expected in Q4 2025.

Financial highlights include $293.7M in cash as of June 30, 2025, collaboration revenue of $22.3M for Q2, and a net loss of $38.6M. The company expects to trigger a $75M milestone payment from GSK when Jemperli reaches $1B in annual sales. AnaptysBio has repurchased 2.85M shares (9.3%) under its stock buyback program and maintains cash runway through 2027.

The company plans to initiate a Phase 1b trial for ANB033 in celiac disease by Q4 2025 and continues Phase 1 trials for ANB033 and ANB101 in healthy volunteers.

AnaptysBio (ANAB) announced positive 6-month data for rosnilimab in Phase 2b trial for moderate-to-severe rheumatoid arthritis. The drug demonstrated JAK-like efficacy with monthly dosing, achieving significant improvements in disease activity measures. The 424-patient trial showed 69% of patients achieved low disease activity (LDA) across all doses at Week 14, with responses lasting at least 2 months after treatment. The drug showed favorable safety with no treatment-related serious adverse events. In b/tsDMARD-naive patients, LDA rates reached up to 72% at Week 28, while b/tsDMARD-experienced patients showed up to 56% LDA. The drug demonstrated ~50% reduction in CRP levels and ~90% reduction in PD-1high T cells, indicating strong anti-inflammatory effects. Rosnilimab targets the ~$20 billion U.S. RA market, with potential for extended dosing intervals during maintenance treatment.

AnaptysBio (NASDAQ: ANAB) has announced it will host an investor call and webcast on June 3, 2025 to present updated data from its global Phase 2b RENOIR clinical trial. The trial evaluates rosnilimab, a PD-1+ T cells depleter and agonist, for treating moderate-to-severe rheumatoid arthritis.

The presentation will feature distinguished speakers including Paul Emery, M.D. from the University of Leeds and Jonathan Graf, M.D. from UCSF. Following the data release, company executives led by CEO Daniel Faga will participate in two major investor conferences: the Jefferies Global Healthcare Conference on June 5 and the Goldman Sachs Global Healthcare Conference on June 11, 2025.

AnaptysBio (NASDAQ: ANAB) reported Q1 2025 financial results and provided key business updates. The company's lead program rosnilimab achieved positive Phase 2b results in rheumatoid arthritis, with upcoming data presentation in June. A Phase 2 trial for ulcerative colitis is ongoing with initial data expected in Q4 2025. The company has $383.0 million in cash as of March 31, 2025, with runway through 2027. Q1 financial highlights include collaboration revenue of $27.8 million (up from $7.2M in Q1 2024) and a net loss of $39.3 million ($1.28 per share). AnaptysBio authorized a $75 million stock repurchase program in March 2025. The company continues to advance its pipeline, including Phase 1a trials for ANB033 and ANB101, while benefiting from its GSK collaboration, which generates substantial royalties from Jemperli sales ($220M in Q1 2025).